Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?

Ascelia Pharma: Potential milestones in 2024

By Claus ThestrupCEO, Sweden
Ascelia Pharma

Wrap up on potentiel milestones in 2024 with CEO Magnus Corfitzen and Deputy CEO Julie Brogren.

Orviglance - readout results in May 2024, Oncoral upstart of Phase 2 trials, Go-to-market strategy is well prepared and focused and finally funding secured until Q2-2025

Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a DigitalIR/Corporate Visibility agreement.

 

Recent videos

Uppesittarkväll 22/12 från Inderes Event Studio
2025-12-22 20:00
Talenom - Planned demerger and strategies of Talenom and Easor
2025-12-18 11:00 Talenom
Conference call with Fabege´s new CEO Bent Oustad
2025-12-18 10:00 Fabege
Investing in the life science sector
2025-12-18 07:47
Life Science Companies as Investments | Life Science Night Dec. 9, 2025
2025-12-16 08:30 Aiforia Technologies
View all videos
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.